Alfentanil and propofol total intravenous anaesthesia was assessed in 25 patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass (CPB). A manually controlled alfentanil infusion, calculated from estimated lean body mass and published pharmacokinetic data, was effective in achieving target plasma concentrations, while the "Diprifusor" system was used to vary propofol target concentrations according to changes in haemodynamics and anaesthetic requirement. The effects of CPB on alfentanil plasma concentrations were offset by changes in protein binding and free-fraction of the drug. With the use of only two target plasma concentrations for alfentanil (changed after CPB), a pre-determined infusion profile ensured effective plasma concentrations during surgery and concentrations unlikely to inhibit extubation within six hours of sternal closure.
Use of an opioid infusion is an important component of intravenous anaesthesia for coronary artery bypass graft (CABG) surgery. The opioid infusion should provide target plasma concentrations during and after cardiopulmonary bypass to provide adequate analgesia, but without delaying extubation or transfer from intensive care. We would define "fasttrack" cardiac surgery as requiring a mean time to extubation less than six hours, as this is usually the limiting factor for transfer from intensive care. The effect of alfentanil in reducing the Cp50 of propofol reaches a plateau above 250 ng.ml -1 1 . Target plasma concentrations above 200 ng ml -1 for CABG delay extubation an average of six hours 2 . Extubation in less than two hours has been reported with low-dose alfentanil and propofol for minimally invasive CABG surgery, but this was without the confounding effect of CPB 3 . We aimed to test a simple manually controlled infusion of alfentanil, with a single reduction in target concentration after CPB, as an adjunct to target-controlled propofol anaesthesia.
METHODS
Institutional ethics committee approval and informed consent was obtained. This paper describes a group of 25 patients randomized to receive intravenous alfentanil rather than epidural analgesia during CABG surgery. During cardiopulmonary bypass, blood temperature was 35°C with rewarming to 36.5°C prior to removal of the cross clamp. Myocardial protection was by anterograde and retrograde blood cardioplegia. Postoperative sedation with propofol was administered only if required, and extubation was performed when the patient was awake and responding to verbal command, core body temperature >36°C, pH >7.3 and P a O 2 >70 mmHg on 40% inspired oxygen. Time to extubation was defined as time from sternal closure to the patient meeting these criteria.
The alfentanil infusion profile was derived from the pharmacokinetic data of Scott and Stanski 4 . Lean body mass (LBM) was estimated from total body weight (TBW, kg) and height (cm) as 1.1 x TBW-128 x(TBW/height) 2 for males and 1.07xTBW-148x (TBW/height) 2 for female patients 5 . The infusion rate was adjusted manually at 1, 5, 10, 20, 30, 40, 60, 90, 120 and 150 minutes after commencing the infusion. For each time interval (commencing 0-1 minutes), estimated plasma drug efflux representing the sum of drug elimination and redistribution from plasma as a function of time 5 was used to calculate infusion rate (73.9, 23.6, 13.7, 8.5, 6.8, 6.2, 5.6, 4.9, 4.4, 4.1 and 3.9 ml.min -1 .LBM -1 ). Infusion rate (µg.min -1 .LBM -1 ) =plasma drug efflux x target concentration (µg ml -1 ). A steady-state target total plasma concentration of 200 ng ml -1 was decreased to 50 ng ml -1 after weaning from CPB. Midazolam 3 to 5 mg was given prior to induction of anaesthesia with a target-controlled infusion of propofol ("Diprifusor" algorithm, AstraZeneca, North Ryde, Australia.). The initial propofol target was 2 µg ml -1 , which was then adjusted according to cardiovascular responses and continued until skin closure.
Blood samples (5 ml) for total and unbound alfentanil concentrations were taken two minutes after sternotomy, during harvest of the internal mammary artery, at commencement of the last distal coronary anastomosis, five minutes after weaning from CPB, at sternal closure and one hour after arrival in the intensive care unit. Blood samples were centrifuged and the plasma stored at -20°C until analysis. The unbound fraction of alfentanil was determined by ultrafiltration of plasma using the MPS-1 micropartition system and YMT membranes (Amicon, Danvers, CO, U.S.A.) at room temperature. Plasma and ultrafiltrate alfentanil analysis was performed using capillary gas chromatography with nitrogen-specific detection.
Total and unbound plasma concentrations of alfentanil were compared "within patients" by repeatedmeasures analysis of variance (Systat 5.0, Systat Inc, Evanston, IL, U.S.A.). Mean prediction error and bias were estimated for the samples taken two minutes after sternotomy and during harvest of the internal mammary artery.
RESULTS
The anaesthetists controlled depth of anaesthesia by adjustment of the propofol infusion and did not request adjustments to the planned alfentanil infusions, or use additional opioids, for any patient. The mean (standard deviation, SD) duration of the surgery was 219 (44) minutes. At sternotomy and prior to CPB mean plasma total alfentanil concentrations were 99% and 107% of the 200 ng.ml -1 target (Figure 1) , with a mean prediction error of 24% (95% confidence interval (CI) ±7%) and mean bias +3% (95% CI, ±12%). Five minutes after commencement of CPB total alfentanil concentration was only 58% of the target. Following weaning from CPB the target concentration of alfentanil was reduced to 50 ng.ml -1 , but the mean total alfentanil concentration was still 188% of this target (94 (41) ng.ml -1 ) when the patients were transferred to the intensive care unit. There was a different pattern of response over time for the unbound versus total plasma concentrations of alfentanil (P<0.001, repeated measures ANOVA, time x binding interaction). Although the total plasma alfentanil concentration decreased, the unbound alfentanil concentration did not change significantly from sternotomy through to weaning from CPB, but declined slowly after the target concentration was reduced (P<0.001). Patients were extubated at mean 271 (SD 138) minutes after sternal closure, with a range 40 to 670 minutes. No patients failed the extubation criteria at greater than 300 minutes because of sedation.
DISCUSSION
Despite a predetermined infusion profile the plasma concentrations of alfentanil prior to CPB were close to our target of 200 ng.ml -1 . Use of estimated LBM rather than total body weight may have improved accuracy. As we had found previously for propofol infusions, the change in total alfentanil concentration with initiation of CPB was almost exactly offset by changes in binding so that concentration of free drug was maintained 6 . The ratio of bound and unbound alfentanil concentrations during CPB correlates with the plasma concentrations of both albumin and alpha 1-acid glycoprotein 7 , suggesting that the decrease in binding during CPB is primarily due to haemodilution.
Plasma concentrations of alfentanil exceeded 100 ng.ml -1 during sternal closure and transfer to the ICU, which provided good analgesia, but respiratory depression was a limiting factor in the time taken to meet criteria for extubation. We consider times to extubation of <6 hours from sternal closure to be compatible with "fast-track" recovery. Use of alfentanil rather than the shorter acting opioid remifentanil also has the advantage that adequate analgesia is provided at the end of surgery without the addition of a long-acting opioid.
CONCLUSIONS
An effective target-controlled infusion of alfentanil, that did not require adjustment for the effects of CPB, was achieved, compatible with extubation within six hours of sternal closure. The algorithm could be easily programmed, or delivered by timed manual adjustment of an infusion pump.
